(Q40287396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Bjørge L

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Stoiber H

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Dierich MP

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

Scandinavian Journal of Immunology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

355-364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16640659%20AND%20SRC:MED&resulttype=core&format=json

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Membrane proteins that protect against complement lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Complement. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Detection and clinical importance of micrometastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Antibody-based immunological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Biological characteristics of micrometastatic cancer cells in bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Complement-regulatory proteins in ovarian malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Complement resistance of tumor cells: basal and induced mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Complement-mediated killing of microtumors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Monoclonal antibodies in the management of ovarian cancer. A clinical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X

Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01751.X